pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
BRISTOL MYERS SQUIBB · news · pharmadog
← back to BRISTOL MYERS SQUIBB
News mentioning BRISTOL MYERS SQUIBB
305
stories
6d
BMS reveals death from septic pneumonia of multiple sclerosis patient in CAR T trial
biospace
6d
BMS sheds light on patient death in CAR-T trial, wants to get program back on track
fiercebiotech
6d
Bristol Myers reveals death in MS CAR-T trial, has answer for safety signal in lupus trial
endpoints
6d
STAT+: Pharmalittle: We’re reading about a cancer vaccine, an experimental pancreatic cancer drug, and more
stat
6d
Pathos raises $237M at $3B valuation, signs Bristol Myers neuro partnership
endpoints
6d
STAT+: AI drug firm Pathos raises $237 million, pushing valuation to $3 billion
stat
6d
Roche bets up to $813M on Zymeworks’ lung cancer trispecific T cell engager
biospace
7d
Treasury sweeps biotech into proposed COINS Act restrictions, but spares Big Pharma’s China licensing deals
fiercebiotech
7d
Critical decisions that spurred these 40 Under 40 winners to success
biospace
8d
Disc’s redemption, China’s rise, Veradermics’ validation, ESMO’s headliners
biospace
8d
Astellas links up with AI Proteins in $400M computational drug discovery deal
fiercebiotech
8d
The 6 biggest crossover rounds in biopharma history
biospace
9d
Hype vs. reality: What pharma’s hottest R&D bets have actually proved
biopharma dive
9d
BMS leads Pathos AI's $237M series E alongside Alzheimer's link-up
fiercebiotech
10d
Pathos inks BMS, Tempus collabs to apply agentic AI in Alzheimer's clinical development
fiercebiotech
14d
AstraZeneca bulks up MASH, cardio work in up to $1.5B AI partnership with insitro
biospace
14d
AstraZeneca inks $1.5B insitro deal for AI-enabled target discovery of liver, heart disease drugs
fiercebiotech
15d
J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback
biospace
16d
BioNTech mRNA cancer immunotherapy misses first objective in key study
biopharma dive
16d
Syndax ends fibrosis program for Niktimvo after mid-stage disappointment
biospace
17d
Bristol Myers dips on ‘confounding’ lung drug results
biopharma dive
17d
BMS’ Phase 3 win for lung drug clouded by high-dose miss
biospace
17d
Bristol Myers reveals a pair of Phase 3 wins for fibrosis, RayzeBio drugs
endpoints
17d
BMS’ $4.1B RayzeBio bet delivers Phase 3 radiopharma win
biospace
17d
Tortugas’ schizophrenia drug proves worth in phase 2 Hansoh trial in China
fiercebiotech
17d
BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growth
fiercebiotech
20d
GSK drinks in Chai Discovery’s AI models after wet-lab validation
fiercebiotech
20d
Hengrui has become the go-to source of China biopharma innovation. What’s its secret?
fiercebiotech
21d
Chutes & Ladders—Vir looks to Liu to lead late-stage push
fiercebiotech
21d
STAT+: Roche goes beyond licensing in deal with Chinese biotech
stat
← prev
page 2 of 11
next →
